Mannose-binding lectin deficiency and acute exacerbations of chronic obstructive pulmonary disease

Richard K Albert, John Connett, Jeffrey L Curtis, Fernando J Martinez, Meilan K Han, Stephen C Lazarus, Prescott G Woodruff, Richard K Albert, John Connett, Jeffrey L Curtis, Fernando J Martinez, Meilan K Han, Stephen C Lazarus, Prescott G Woodruff

Abstract

Background: Mannose-binding lectin is a collectin involved in host defense against infection. Whether mannose-binding lectin deficiency is associated with acute exacerbations of chronic obstructive pulmonary disease is debated.

Methods: Participants in a study designed to determine if azithromycin taken daily for one year decreased acute exacerbations had serum mannose-binding lectin concentrations measured at the time of enrollment.

Results: Samples were obtained from 1037 subjects (91%) in the trial. The prevalence of mannose-binding lectin deficiency ranged from 0.5% to 52.2%, depending on how deficiency was defined. No differences in the prevalence of deficiency were observed with respect to any demographic variable assessed, and no differences were observed in time to first exacerbation, rate of exacerbations, or percentage of subjects requiring hospitalization for exacerbations in those with deficiency versus those without, regardless of how deficiency was defined.

Conclusion: In a large sample of subjects with chronic obstructive pulmonary disease selected for having an increased risk of experiencing an acute exacerbation of chronic obstructive pulmonary disease, only 1.9% had mannose-binding lectin concentrations below the normal range and we found no association between mannose-binding lectin concentrations and time to first acute exacerbation or frequency of acute exacerbations during one year of prospective follow-up.

Trial registration: ClinicalTrials.gov NCT00325897.

Keywords: COPD; acute exacerbations; mannose-binding lectin.

Figures

Figure 1
Figure 1
Proportions free of exacerbations MBL concentrations A) subjects receiving azithromycin (B) and in subjects receiving the placebo (C). Abbreviations: COPD, chronic obstructive pulmonary disease; MBL, mannose binding lectin.
Figure 2
Figure 2
Proportions free of exacerbations MBL concentrations A) subjects receiving azithromycin (B) and in subjects receiving the placebo (C). Abbreviations: COPD, chronic obstructive pulmonary disease; MBL, mannose binding lectin.
Figure 3
Figure 3
Proportions free of exacerbations MBL concentrations between 50 and 1000 vs 1000 or larger in all subjects (A) subjects receiving azithromycin (B) and in subjects receiving the placebo (C). Abbreviations: COPD, chronic obstructive pulmonary disease; MBL, mannose binding lectin.

References

    1. Ikeda K, Sannoh T, Kawasaki N, Kawasaki T, Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J Biol Chem. 1987;262:7451–7454.
    1. Thiel S, Vorup-Jensen T, Stover CM, et al. A second serine protease associated with manna-binding lectin that activates complement. Nature. 1997;386:506–510.
    1. Soell M, Lett E, Holveck F, Scholler M, Wachsmann D, Klein JP. Activation of human monocytes by streptococcal rhamnose glues polymers is mediated by CD14 antigen and mannan binding protein inhibits TNF-alpha release. J Immunol. 1995;154:851–860.
    1. Chaka W, Verheul AF, Vaishnav VV, et al. Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J Immunol. 1997;159:2979–2985.
    1. Jack DL, Read RC, Tenner AJ, Frosch M, Turner MW, Klein NH. Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitides serogroup B. J Infect Dis. 2001;184:1152–1162.
    1. Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RAB. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J Immunol. 2005;174:3220–3226.
    1. Masden HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein concentrations of mannan-binding lectin in populations from southeast Africa and South America. J Immunol. 1998;161:3169–3175.
    1. Thiel S, Frederiksen PD, Hensenius JC. Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol. 2006;43:86–96.
    1. Bronkhorst MW, Bouwman LH. Mannose-binding lectin deficiency. UpToDate®. Available from: . Accessed September 3, 2010.
    1. Neth O, Jack DL, Dodds AW, Holzel HJ, Klein MH, Turner MW. Mannose-binding lectin binds to a range of clinically relevant micro-organisms and promotes complement deposition. Infect Immun. 2000;68:688–693.
    1. van Emmerick LC, Kuijper EJ, Fifjen CA, Dankert J, Thiel S. Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin Exp Immunol. 1994;97:411–416.
    1. Hamvas RM, Johnson M, Vlieger AM, et al. Role for mannose binding lectin in the prevention of Mycoplasma infection. Infect Immun. 2005;73:5238–5240.
    1. Anders EM, Hartley CA, Reading PC, Ezekowitz RA. Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin. J Gen Virol. 1994;75:615–622.
    1. Garred P, Pressler T, Madsen HO, et al. Association of mannose-blinding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest. 1999;104:431–437.
    1. Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ. 1999;319:1166–1167.
    1. Yarden J, Radojkovic D, De Boeck K, et al. Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J Med Genet. 2004;41:629–633.
    1. Davies JC, Turner MW, Klein N, London MBL CF Study Group Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J. 2004;24:798–804.
    1. Koch A, Melbye M, Sorensen P, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA. 2004;285:1316–1321.
    1. Gomi K, Tokue Y, Kobayashi T, et al. Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections. Chest. 2004;126:95–99.
    1. Rantala A, Lajunen T, Juvonen R, et al. Mannose-binding lectin concentrations, MBL2 polymorphisms and susceptibility to respiratory tract infections in young men. J Infect Dis. 2008;198:1247–1253.
    1. Hoeflich C, Unterwalder N, Schuett S, et al. Clinical manifestations of MBL deficiency in adults independent of concomitant immunodeficiency. Hum Immunol. 2009;70:809–812.
    1. Ribeiro LZG, Tripp RA, Rossi LMG, et al. Serum mannose-binding lectin concentrations are linked with respiratory syncytial virus (RSV) disease. J Clin Immunol. 2008;28:166–173.
    1. Roy S, Knox K, Segal SH, the Oxford Pneumococcal Surveillance Group MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet. 2002;359:1569–1573.
    1. Ip WKE, Chan KH, Law HKW, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2005;191:1697–1704.
    1. Eisen DP, Dean MM, Boermeester MA, et al. Low serum mannose-binding lectin concentration increases the risk of death due to pneumococcal infection. Clin Infect Dis. 2008;47:510–520.
    1. Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F, et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol. 2008;122:368–374.
    1. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:139–148.
    1. Hodge S, Matthews G, Dean MM, et al. Therapeutic role for mannose- binding lectin in cigarette smoke-induced lung inflammation? Evidence from a murine model. Am J Respir Cell Mol Biol. 2010;42:235–242.
    1. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. A polulation-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med. 2004;199:1391–1399.
    1. Yang IA, Sleeney SL, Wolter JM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun. 2003;4:269–274.
    1. Eagan TML, Aukrust P, Bakke PS, et al. Systemic mannose-binding lectin is not associated with chronic obstructive pulmonary disease. Respir Med. 2010;104:283–290.
    1. Lin C-L, Siu LK, Lin J-C, et al. Mannose-binding lectin gene polymorphism contributes to recurrence of infective exacerbation in COPD patients. Chest. 2011;139:43–51.
    1. Albert RK, Connett J, Bailey WC, et al. COPD Clinical Research Network Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698.
    1. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317–326.
    1. Minchinton RM, Dean MM, Clark TR, Heatley S, Mullighan CG. Analysis of the relationship between mannose-binding lectin (MBL) genotyhpe, MBL concentrations and function in an Australian blood donor population. Scand J Immunol. 2002;56:630–641.
    1. Saevarsdottir S, Kristjansdottir H, Grondal G, Vikingsdottir T, Steinsson K. Mannan-binding lectin and complement C4A in Icelandic multi-case families with systemic lupus erythematosus. Ann Rheum Dis. 2006;65:1462–1467.
    1. Christiansen OB, Kilpatrick DC, Souter V, Varming K, Thiel S, Jensenius JC. Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand J Immunol. 1999;49:193–199.
    1. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods. 2000;241:33–42.
    1. Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet. 2001;358:637–638.
    1. Kruse C, Rosgaard A, Steffesnsen R, Varming K, Jensenius JC, Christiansen OB. Low serum concentration of mannan-binding lectin is a determinant for pregnancy outcome in women with recurrent spontaneous abortion. Am J Obstet Gynecol. 2002;187:1313–1320.
    1. Ezekowitz RA, Day LE, Herman GA. A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med. 1988;167:1034–1046.
    1. Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC. The concentration of the C-type lectin, mannan-binding protein, in human increases during an acute phase response. Clin Exp Immunol. 1992;99:311–315.
    1. van Till JWO, Boermeester MA, Modderman PW, et al. Variable mannose-binding lectin expression during postoperative acute-phase response. Surg Infect (Larchmt) 2006;7:443–452.
    1. Ip W, To YF, Cheng SK, Lau YL. Serum mannose-binding lectin concentrations and mbl2 gene polymorphisms in different age and gender groups of southern Chinese adults. Scand J Immunol. 2004;59:310–314.
    1. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens. 2006;68:193–209.
    1. Dean MM, Minchinton RM, Heatley S, Eisen DP. Mannose binding lectin acute phase activity in patients with severe infection. J Clin Immunol. 2005;25:346–352.
    1. Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol. 2006;67:247–256.
    1. Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun. 2010;2:114–122.
    1. Kuipers S, Aerts PC, van Dijk H. Differential microorganism-induced mannose-binding lectin activation. FEMS Immunol Med Microbiol. 2003;36:33–39.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera